SH-1028 clinical trials
Also written SH-1028.
How each study uses SH-1028 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the SH-1028 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
8 studies that test it; most in 2018 (2)
| Year | Studies |
|---|---|
| 2018 | 2 |
| 2019 | 2 |
| 2020 | 2 |
| 2021 | 1 |
| 2023 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 8 · Other 0
Studies
Open first, then newest update. How each study uses SH-1028 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 8
- SH-1028 Tablets Versus Placebo as Adjuvant Therapy in Resected Stage II-IIIB NSCLC With Sensitizing EGFR MutationsRecruitingPhase 3Nanjing Sanhome Pharmaceutical, Co., Ltd.NCT06080776Written as SH-1028 tabletsHow we know
- The Absorption, Metabolism and Excretion of [14C]SH-1028 in Chinese Healthy Male VolunteersCompletedPhase 1Nanjing Sanhome Pharmaceutical, Co., Ltd.NCT04810533Written as [14C] SH-1028How we know
- The Effect of Itraconazole and Rifampicin on the Pharmacokinetics of SH-1028Status unknownPhase 1Nanjing Sanhome Pharmaceutical, Co., Ltd.NCT04808648Written as SH-1028How we know
- A Study of SH-1028 Tablets Versus Gefitinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung CancerStatus unknownPhase 3Nanjing Sanhome Pharmaceutical, Co., Ltd.NCT04239833Written as SH-1028 tabletsHow we know
- Pharmacokinetic Study of SH-1028 Tablets in Healthy Subjects Under Fasting and Fed ConditionsStatus unknownPhase 1Nanjing Sanhome Pharmaceutical, Co., Ltd.NCT03973632Written as SH-1028 TabletsHow we know
- A Study to Evaluate the Safety and Efficacy of SH-1028 in Locally Advanced or Metastatic NSCLCStatus unknownPhase 2Nanjing Sanhome Pharmaceutical, Co., Ltd.NCT03823807Written as SH-1028How we know
- Safety and Tolerability of SH-1028 in Patients With Advanced Solid CancerStatus unknownPhase 1Nanjing Sanhome Pharmaceutical, Co., Ltd.NCT03618043Written as SH-1028How we know
- Safety, Tolerability and Pharmacokinetics of SH-1028 in Patients With Advanced NSCLCStatus unknownPhase 1Nanjing Sanhome Pharmaceutical, Co., Ltd.NCT03603262Written as SH-1028How we know